Degree in Biological Sciences from University of Sao Paulo, MsC in Molecular Biology from University of Brasília and PhD in Genetics from University of São Paulo. Research assistant in Genetics Biochemistry at University College London and post doctorate in Cell Biology at University of Turin. Has experience on the development of monoclonal antibodies, humanized and human mAbs, cell line generation, upstream, downstream, analytical methods. Supervisor of PhD in Biotechnology and Immunology programs at University of Sao Paulo. Scientific Researcher and Lab Director of Biopharmaceuticals at Instituto Butantan. Coordinator of institutional research programs. Developed projects with private companies (Recepta Bio and Libbs Farmacêutica). (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| El hito de los anticuerpos |
| El hito de los anticuerpos |
| Antibody milestone |
| Building a drug |
| La concepción de un medicamento |
| Alta productividad |
| High productivity |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The development of biopharmaceuticals involves several complex steps that demand a lot of time and resources, in addition to the risks of failure. When working with monoclonal antibodies (mAbs), the unpredictability factor is high because it depends on finding, among the peripheral blood B cells, or among the B cells of organs of immunized animals, the only ones that express the antibody(…
Instituto Butantan (IB), has always worked to answer public health challenges and has a long tradition in the development and manufacturing of vaccines and antibodies. This project addresses both areas, influenza vaccines and human monoclonal antibodies, focusing on critical targets that demand attention and require the use of strategies based on solid scientific, clinical, regulatory and…
Antibodies are considered magic bullets, and monoclonal antibodies (mAbs), displaying fine specificity binding for the target, represent today a great clinical and commercial success. There are currently 48 approved mAbs for therapeutic use, 26 targeted to cancer treatment, 10 targeted to auto-immune diseases, 12 targeted to antigens related to other clinical situations and hundreds in di…
Antibodies, being specific in their antigen binding and capable of neutralization, have been used since the beginning of 20th century for treatment of various infectious diseases, including pneumococcal pneumonia, meningococcal meningitis, erysipelas, anthrax and others (Casadevall and Scharff, 1994; Casadevall and Scharff, 1995). Serum-therapy was established as a powerful tool for the c…
This project, conducted between Instituto Butantan and PR&D/Recepta biopharma under Fapesp's Partnership for Technological Innovation program (PITE) , aims to generate cell lines for the production of humanized monoclonal antibodies (Hu-Mabs). Those recombinant cell lines will be the basis for the future GMP production and use of the Hu-Mabs by Recepta to test their efficacy on cancer pa…
(Only some records are available in English at this moment)
Diphtheria is a fatal disease caused by infection with Corynebacterium diphtheriae, a bacterium that, when infected by a corynebacteriophage, begins to carry the tox gene sequence, which encodes the diphtheria toxin. Individuals affected by the disease exhibit cell death at the sites of toxin production, with characteristic lesions in the pharynx and skin. In more severe cases, where ther…
At the Butantan Institute's Biopharmaceuticals Laboratory, 3 monoclonal antibodies (mAbs) were identified that, together, neutralize tetanus toxin in an in vivo study in mice. The result is compared to that obtained by equine hyperimmune polyclonal serum produced at Butantan, in a pharmacopeial test. The mAbs, expressed by transient transfection, were characterized by Western blot, ELISA,…
(Only some records are available in English at this moment)
The Biopharmaceuticals Laboratory has a tradition in the discovery, development and characterization of monoclonal antibodies with therapeutic potential for infectious diseases. Recently, the laboratory produced and characterized a variety of human anti-tetanus and anti-Sars-Cov-2 antibodies in their integral format, that is, complete IgG. However, there was a need to produce and study an…
During the generation of recombinant monoclonal antibodies, one of the essential steps is the expression of light and heavy chain sequences in mammalian cells. The transient transfection process is usually done by co-transfecting two vectors, one cloned with the heavy chain and the other cloned with the light chain. The co-transfection is satisfactory when the balancing of the two vectors…
Tetanus remains a global health issue and reflects the precariousness of the health public system in underdeveloping countries. Although the complete immunization schedule is offered in Brazil, the Ministry of Health of Brazil disclose about a hundred new cases of accidental tetanus by year. In cases of infection, it is recommended the use of animal or human serum (passive immunization), …
(Only some records are available in English at this moment)
| 2 / 2 | Ongoing research grants |
| 8 / 4 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 15 / 13 | Completed scholarships in Brazil |
| 29 / 23 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID